Ferronova

RAGE Biotech is a biotechnology industry.

Propanc is a company that conducts research and development to create therapies for cancer and other long-lasting illnesses. Their main focus is on crafting innovative treatments for patients with pancreatic, ovarian, and colorectal cancer.

Kazia Therapeutics is a biotechnology company specializing in oncology, creating groundbreaking anti-cancer medications. The company partners with top researchers, doctors, and investors globally.

Levur creates oils that are chemically identical to natural oils but without harming the environment. Our goal is to decrease our dependency on unsustainable oils like Palm Oil and Tallow to help lessen environmental damage. Based in Australia, we are working with major consumer goods companies to make this vision a widespread reality and provide ethical alternatives to customers globally.

AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes attached to molecules, which can deliver targeted radiation to tumors at the molecular level. This approach enables healthcare providers to offer safe and efficient treatment options for various types of cancer.

Ena Respiratory is a biotechnology company focused on revolutionizing the way respiratory infections are treated and prevented, as well as improving the efficacy of vaccines. Their innovative synthetic Toll-like receptor 2 (TLR2) agonists have demonstrated the ability to stimulate the innate immune system in the respiratory tract, thereby halting the spread of viruses and bacteria to the lungs.

Psylo is a company that specializes in developing advanced psychedelics for medicinal purposes. Our objective is to create more widely available drugs that offer better treatment than traditional SSRI medications, using psychedelic compounds as a foundation. We are working on a range of innovative molecules with the aim of eventually conducting clinical trials on the most promising candidates.

We help companies within the paper industry–and their customers–who want to move to circular models of production. We’ve listened to our customers to learn what properties they need in their coatings. And we’ve created these using 100% bio-based ingredients. We’ve made them easy to apply using existing equipment. So there’s no need to invest in expensive new systems. Because we want to help as many companies as possible join the circular economy. Our customers are: - Paper manufacturers - Paper coaters - Packaging companies - Consumer brands who are embracing a circular future. Get in touch to learn more about our products and how we can help you transition to circular systems.

Orthocell is a regenerative medicine company dedicated to the development of breakthrough products to unlock the power of the human body to heal - restoring mobility, function and performance. Orthocell produces two complementary platform products – a collagen medical device and autologous cell therapies. CelGro™ platform of collagen medical devices are designed to augment surgical repair of bone, nerve, tendon and cartilage. The Company’s cell therapies include autologous tendon therapy and autologous chondrocyte implantation (OrthoACI™), which aim to regenerate damaged tendon and cartilage tissue.

Atomo Diagnostics, a medical device company based in Sydney, Australia, has offices in South Africa and the United Kingdom. The company was founded on the belief that healthcare products offering greater convenience, simplicity, and user experience can be highly disruptive and successful in the commercial market. In 2013, Atomo introduced AtomoRapid, a range of professional tests designed for fast and accurate results in clinical and community settings. The AtomoRapid HIV test received the Best in Show award at the Medical Device Excellence Awards (MDEA) in 2014, and Atomo was recognized as the Australian Emerging Company of the Year by Johnson & Johnson Innovation. Atomo is dedicated to improving early detection and treatment of infectious and chronic diseases by providing safer, more accurate, and more accessible testing options. For more information on the company and its products, visit www.atomodiagnostics.com.

Kinoxis Therapeutics, an emerging biotechnology company located in Australia, is focused on advancing the development of innovative therapeutic compounds for substance use disorders and other conditions affecting the central nervous system. The company has acquired the rights to these compounds from the University of Sydney, with the primary candidate showing promising effects in various animal studies and is currently undergoing preclinical trials.

Despite being a global leader in the creation of intellectual property in drug development and medical equipment, Australia does not capitalize on the downstream benefits and job opportunities that come with commercializing this IP. This is because of a lack of advanced domestic preclinical expertise. Proto Axiom is changing this by enhancing Australia's capacity in this area, thus allowing Australian IP to remain in the country.